Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity
Frontiers in Bioscience-Landmark · 2023
DOI: 10.31083/j.fbl2805097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Zhu Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Affiliated Drum Tower Hospital, Medical School, Nanjing University, 210008 Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Bulimia, Metformin, Diabetes Mellitus, Type 2. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health.
Abstract (Originalsprache)
Background
Obesity is primarily a consequence of food addiction. Drugs have been confirmed effective for weight loss more or less related to the functional connectivity in neural networks and metabolic patterns. Recent studies have shown that some anti-diabetic drugs, such as Metformin and Dapagliflozin have similar weight loss effects, however, their mechanisms are unclear. We hypothesized that the functional connectivity and energy metabolism might be associated with the mechanisms.
Methods
Male ob/ob mice were fed with high-fructose-fat-diet (HFFD) for 4 weeks to esteblish obesity model. Then mice were divided into normal saline (NS, as control), Metformin (Metformin, 50 mg/kg/day by gavage), and Dapagliflozin (Dapagliflozin, 10 mg/kg/day by gavage) groups. Functional connectivity amplitude of low-frequency signal fluctuations and regional cerebral blood volume (rCBV) quantification were statistically analyzed in the linear mixed model, meanwhile, metabolic pattern of intestinal cells (IECs) were also tested.
Results
Our results showed that Blood Oxygen on Level Depending (Bold) signaling responses, functional connectivity, and rCBV quantification tended to be attenuated in the Metformin group compared to the control and Dapagliflozin groups. While only Dapagliflozin prevented HFFD induced hyper survival of intestinal cells and hypertrophy of intestinal villus by reducing glycolysis levels. Both Metformin and Dapagliflozin are effective for weight loss.
Conclusions
Our findings showed that Dapagliflozin and Metformin may inhibit bulimia induced obesity with different mechanisms. We speculate that Metformin may affect appetite regulation, while Dapagliflozin can affect the survival and metabolic patterns of intestinal cells, thus significantly affecting the absorption of nutrients. So, combining Metformin and Dapgliflozin may be more beneficial for clinical improvement in bulimia induced obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Affiliated Drum Tower Hospital, Medical School, Nanjing University, 210008 Nanjing, Jiangsu, China.
- Department of Medical Laboratory, Affiliated Drum Tower Hospital, Medical School, Nanjing University, 210008 Nanjing, Jiangsu, China.
- Department of Medical Imaging, Affiliated Drum Tower Hospital, Medical School, Nanjing University, 210008 Nanjing, Jiangsu, China.
Förderung
- Natural Science Foundation of China
- Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health
Zitieren
APA
Li, Z., Jia, J., Hao, H., Qiao, S., Zhang, Q., Zhang, X., Qi, Y., Sun, X., Wang, K., Gu, R., Kang, L., & Xu, B. (2023). Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2805097
Vancouver
Li Z, Jia J, Hao H, Qiao S, Zhang Q, Zhang X, et al. Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2805097
BibTeX
@article{Li2023,
author = {Li, Zhu and Jia, Jia and Hao, Han and Qiao, Shiyang and Zhang, Qinglei and Zhang, Xinlin and Qi, Yu and Sun, Xuan and Wang, Kun and Gu, Rong and Kang, Lina and Xu, Biao},
title = {Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity},
journal = {Frontiers in Bioscience-Landmark},
year = {2023},
doi = {10.31083/j.fbl2805097}
}
EUVIMED